Table 1.
Patient baseline characteristics
| GEM-E (n = 1,331) | GEM (n = 2,936) | p-valuea | |
|---|---|---|---|
| No. (%) | No. (%) | ||
| Sex | |||
| Male | 861 (64.69) | 1,743 (59.37) | 0.0010 |
| Female | 470 (35.31) | 1,193 (40.63) | |
| Age, years | |||
| Mean ± SD | 61.89 ± 9.76 | 63.38 ± 10.40 | <0.0001 |
| Median | 63 | 65 | |
| Range | 28–88 | 18–92 | |
| 18–29 | 2 (0.15) | 6 (0.20) | <0.0001 |
| 30–39 | 16 (1.20) | 42 (1.43) | |
| 40–49 | 128 (9.62) | 268 (9.13) | |
| 50–59 | 387 (29.08) | 683 (23.26) | |
| 60–69 | 486 (36.51) | 1,010 (34.4) | |
| 70–79 | 295 (22.16) | 825 (28.1) | |
| Above 80 | 17 (1.28) | 102 (3.47) | |
| Charlson Comorbidity Index (CCI) | |||
| Mean ± SD | 8.88 ± 3.39 | 9.14 ± 3.40 | 0.0206 |
| Median | 10 | 10 | |
| Range | 2–18 | 2–19 | |
| Comorbidity score | |||
| ≤ 3 | 102 (7.66) | 222 (7.56) | 0.2024 |
| 4–6 | 246 (18.48) | 476 (16.21) | |
| 7–9 | 302 (22.69) | 664 (22.62) | |
| 10–12 | 511 (38.39) | 1,134 (38.62) | |
| ≥ 13 | 170 (12.77) | 440 (14.99) | |
| Follow-up time, daysb | |||
| Mean ± SD | 278.7 ± 224.7 | 292.3 ± 263.3 | |
| Median | 210 | 207 | |
Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
aDifferences between GEM and GME-E were tested with t-test for continues variable and with the chi-square test for categorical variables
bFollow-up termination: follow-up for 3 years or until December 31, 2013 or date of death